A Phase 3 Trial of Upadacitinib for Giant-Cell Arteritis

Melanoma and Skin Cancer

Retifanlimab with carboplatin and paclitaxel for locally recurrent or metastatic squamous cell carcinoma of the anal canal (POD1UM-303/InterAACT-2): a global, phase 3 randomised controlled trial

Lancet

Rao S, Samalin-Scalzi E, Evesque L, Ben Abdelghani M, Morano F, Roy A, Dahan L, Tamberi S, Dhadda AS, Saunders MP, Casanova N, Guimbaud R, Lievre A, Maurel J, Fakih M, Tian C, Harrison J, Jones MM, Cornfeld M, Spano JP, Rochefort P, POD1UM-303/InterAACT-2 study investigators

doi: 10.1016/S0140-6736(25)00631-2

Immune Response

A Phase 3 Trial of Atacicept in Patients with IgA Nephropathy

N Engl J Med

Lafayette R, Barbour SJ, Brenner RM, Campbell KN, Doan T, Eren N, Floege J, Jha V, Kim BS, Liew A, Maes B, Pal A, Pecoits-Filho R, Phoon RKS, Rizk DV, Suzuki H, Tesař V, Trimarchi H, Wei X, Zhang H, Barratt J, ORIGIN Phase 3 Trial Investigators

doi: 10.1056/NEJMoa2510198

Further Publications Rheumatology

Tocilizumab in cranial and extracranial giant cell arteritis: a national multicenter study of 471 cases

Rheumatology (Oxford)

Blanco R, Aldasoro V, Maiz O, Melero R, Romero-Yuste S, de Miguel E, Ferraz-Amaro I, López-Gutiérrez F, Castañeda S, Loricera J, Tocilizumab in Giant Cell Arteritis Spanish Collaborative Group

doi: 10.1093/rheumatology/keae666

Psoriasis

Roflumilast Foam, 0.3%, for Psoriasis of the Scalp and Body: The ARRECTOR Phase 3 Randomized Clinical Trial

JAMA Dermatol

Gooderham MJ, Alonso-Llamazares J, Bagel J, Bhatia N, Bukhalo M, DuBois J, Ferris LK, Green L, Kircik LH, Lockshin B, Loo WJ, Papp KA, Soung J, Seal MS, Snyder S, Kato S, Krupa D, Burnett P, Berk DR, Chu DH

doi: 10.1001/jamadermatol.2025.1136

Atopic Dermatitis

Skin Clearance, Duration of Treatment-free Interval, and Safety of Tapinarof Cream 1% Once Daily: Results from ADORING 3, a 48-week Phase 3 Open-label Extension Trial in Adults and Children Down to 2 Years of Age with Atopic Dermatitis

J Am Acad Dermatol

Bissonnette R, Gold LS, Kircik L, Simpson EL, Eichenfield LF, Browning J, Hebert AA, Alexis AF, Soong W, Piscitelli SC, Tallman AM, Rubenstein DS, Brown PM, Silverberg JI

doi: 10.1016/j.jaad.2025.05.1391

Systemic Lupus Erythematosus

A Phase 3 Trial of Telitacicept for Systemic Lupus Erythematosus

N Engl J Med

van Vollenhoven RF, Wang L, Merrill JT, Liu Y, Bao C, Li F, Hu J, Huang C, Zhao J, Huang C, Mo H, Wei W, Lu F, Li J, Zhao D, Wang W, Li L, Zuraw Q, Wang X, Wang X, Fang J, Zhang F, 18C010 Trial Investigators

doi: 10.1056/NEJMoa2414719

Further Publications Immunology

Sibeprenlimab in IgA Nephropathy - Interim Analysis of a Phase 3 Trial

N Engl J Med

Perkovic V, Trimarchi H, Tesar V, Lafayette R, Wong MG, Barratt J, Suzuki Y, Liew A, Zhang H, Carroll K, Jha V, Quevedo A, Han SH, Praga M, Chacko B, Sahay M, Cheung CK, Kooienga L, Walsh M, Xia J, Fajardo C, Shah L, Hafkin J, Rizk DV, VISIONARY Trial Investigators Group

doi: 10.1056/NEJMoa2512133

Further Publications Rheumatology

Upadacitinib in active non-radiographic axial spondyloarthritis: 2-year data from the phase 3 SELECT-AXIS 2 study

Arthritis Res Ther

Van den Bosch F, Deodhar A, Poddubnyy D, Maksymowych WP, van der Heijde D, Kim TH, Kishimoto M, Baraliakos X, Bu X, Lagunes-Galindo I, Song IH, Wung P, Kato K, Shmagel A

doi: 10.1186/s13075-024-03441-3

Further Publications Rheumatology

Cerebrovascular accidents in giant cell arteritis: prevalence and predictive factors from the ARTESER registry

Rheumatology (Oxford)

Martín-Gutiérrez A, Molina-Collada J, Domínguez-Álvaro M, Melero-González RB, Fernández-Fernández E, Silva-Díaz M, Valero JA, González I, Martín JS, Narváez J, Calvo I, Aldasoro V, Abasolo Alcázar L, Loricera J, Ruíz-Roman A, Castañeda S, Molina-Almela C, Alcalde Villar M, Juan Mas A, Blanco R, ARTESER Project Collaborative Group

doi: 10.1093/rheumatology/keaf051

Related content

Retifanlimab with carboplatin and paclitaxel for locally recurrent or metastatic squamous cell carcinoma of the anal canal (POD1UM-303/InterAACT-2): a global, phase 3 randomised controlled trial

A Phase 3 Trial of Atacicept in Patients with IgA Nephropathy

Tocilizumab in cranial and extracranial giant cell arteritis: a national multicenter study of 471 cases

Roflumilast Foam, 0.3%, for Psoriasis of the Scalp and Body: The ARRECTOR Phase 3 Randomized Clinical Trial

Skin Clearance, Duration of Treatment-free Interval, and Safety of Tapinarof Cream 1% Once Daily: Results from ADORING 3, a 48-week Phase 3 Open-label Extension Trial in Adults and Children Down to 2 Years of Age with Atopic Dermatitis

A Phase 3 Trial of Telitacicept for Systemic Lupus Erythematosus

Sibeprenlimab in IgA Nephropathy - Interim Analysis of a Phase 3 Trial

Upadacitinib in active non-radiographic axial spondyloarthritis: 2-year data from the phase 3 SELECT-AXIS 2 study

Cerebrovascular accidents in giant cell arteritis: prevalence and predictive factors from the ARTESER registry